Through technology license agreement with San Diego Regenerative Medicine Institute, Xcelthera Inc has become the first in the world to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell
lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses.
Importantly, beating cardiomyocytes derived from ES cell
EBs function in all manners as cardiac cells, forming stable intracardiac grafts when injected into mice (Klug et al.
The vast majority of scientists believed that nuclear reprogramming would require the use of early ES cells
, via nuclear transfer or cell fusion.
In consequence of the ethical difficulties of obtaining fertilised human eggs, numerous ES cell
lines have been created.
The four ICM-derived cell clumps from hybrid mice formed ES cell
colonies at the first passage.
The assay systems were developed to expand the capabilities of VistaGen's ES Cell
technologies to discover novel biologic products to treat diabetes and to accelerate Sanwa's internal discovery and screening programs for new small molecule drug candidates for Type 1 and Type 2 diabetes.
The company's industry advantage is built around the use of its proprietary ES Cell
technology platform as a customizable, therapeutically-focused predictive toxicology and drug discovery engine.
91) The public interest in ES cell
research and the potential benefits are indeed awesome.
The Company's process for differentiating ES cells
to retinal pigmented epithelial (RPE) cells is not permissive to ES cell
persistence in the culture.
Some current research using ES cell
lines raises questions about whether animals are being used without any clear sense of what benefits are expected.
NYSE Amex: BTIM) filed an amendment to its Current Report on Form 8-K with the Securities and Exchange Commission reporting BioTime's acquisition of ES Cell
International Pte Ltd, a Singapore private limited company ("ESI").
BULLETIN BOARD: OTCI) , a company focused on advancing regenerative medicine through the development of cellular technology and advanced biomaterial products, announced today that their collaboration with ES Cell
International Pte, Ltd.